Overview

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will receive adjuvant taxane-based chemotherapy (i.e. docetaxel and cyclophosphamide with trastuzumab [TC-H] or weekly paclitaxel with trastuzumab [P-H]) at the standard approved doses, aiming to gather more information regarding cost-effectiveness, toxicity, quality of life (QoL), patient reported outcomes and clinical benefits of the two treatment strategies.

Phase:

Phase 3

Details

Lead Sponsor:

Lawson Health Research Institute
London Health Sciences Centre

Collaborator:

The Ottawa Hospital

Treatments:

Albumin-Bound Paclitaxel
Cyclophosphamide
Docetaxel
Paclitaxel
Trastuzumab